Who are Pharvaris N.V.'s main suppliers?

Pharvaris N.V. (PHVS) key suppliers include: CDMOS. View the full supplier network at chainsifter.com/chain/PHVS.

Who are Pharvaris N.V.'s major customers?

Pharvaris N.V. (PHVS) key customers include: BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Morgan Stanley, Morgan Stanley, Myriad Genetics, Inc. and 10 more. View the full customer network at chainsifter.com/chain/PHVS.

What sector is Pharvaris N.V. in?

Pharvaris N.V. (PHVS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Pharvaris N.V. Supply Chain Data (PHVS): 17 Verified Relationships

1Suppliers

15Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Pharvaris N.V. (PHVS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

1Distinct source URLs

3High confidence

0.723Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Pharvaris N.V. Suppliers

Ticker	Name	Confidence	Evidence
CDMOS	CDMOS	92%	We currently rely on a small number of CDMOs for the production of certain of our product candidates

Pharvaris N.V. Customers

Ticker	Name	Confidence	Evidence
BMRN	BioMarin Pharmaceutical Inc.	72%	ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale…
BMRN	BioMarin Pharmaceutical Inc.	72%	Reciprocal relationship from BMRN graph: Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respec…
MS-PE	Morgan Stanley	72%	Reciprocal relationship from MS-PE graph: Reciprocal relationship from PHVS graph: written offering. The Offering closed on December 8, 2023, and the Company generated net proceeds of $ 282.0 million…
MS-PK	Morgan Stanley	72%	written offering. The Offering closed on December 8, 2023, and the Company generated net proceeds of $ 282.0 million (€ 261.6 million), after deducting bank fees of $ 18.0 million (€ 16.7 million). T…
MYGN	Myriad Genetics, Inc.	72%	ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts …
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to ge…
RYTM	Rhythm Pharmaceuticals, Inc.	72%	Reciprocal relationship from RYTM graph: Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respec…
RYTM	Rhythm Pharmaceuticals, Inc.	72%	ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale…
SNYNF	Sanofi	72%	ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from SNYN…
ABBV	AbbVie Inc.	62%	Reciprocal relationship from ABBV graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from ABBV g…
JNJ	Johnson & Johnson	62%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from JNJ grap…
LITB	LightInTheBox Holding Co., Ltd.	62%	Reciprocal relationship from LITB graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from LITB graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from LITB g…
PASSIVE-FOREIGN-INVESTMENT-COMPANY	PASSIVE-FOREIGN-INVESTMENT-COMPANY	62%	nd €0.6 million, respectively. A new agreement was entered into with GrayMatters, effective December 1, 2023 to November 30, 2027. The agreement provides for daily fixed fees up to a maximum amount p…
QUESTCOR-PHARMACEUTICALS-INC	QUESTCOR-PHARMACEUTICALS-INC	62%	eveloped a broad human resources background, working in human resources leadership roles at European, international and global levels with companies such as Shire Pharmaceuticals (April 2018 - March …

Pharvaris N.V. Debt Obligations

Instrument	Description	Confidence	Evidence
PHVS-DEBT	Debt stack $861,479	90%	Market cache reports total debt of $861,479.

Pharvaris N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Pharvaris N.V..

Pharvaris N.V. Ownership

Holder	Name	Confidence	Evidence
PHVS-OWNER-GENERAL-ATLANTIC-L-P	GENERAL ATLANTIC, L.P.	90%	13F overlay lists GENERAL ATLANTIC, L.P. as top holder; 111 tracked holders.

Pharvaris N.V. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BNTC	Benitec Biopharma Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2

Pharvaris N.V. Supply Chain